Evidence map›Paper›PMID 36818343›Full record

ReviewFrontiers in cardiovascular medicine2023

Mesenchymal stem cell-based therapy for non-healing wounds due to chronic limb-threatening ischemia: A review of preclinical and clinical studies.

Carlos Theodore Huerta, Francesca A Voza, Yulexi Y Ortiz, Zhao-Jun Liu, Omaida C Velazquez

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
11.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Mesenchymal stromal cell therapy (REGENACIPStem cell research & therapy · 2024
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Carlos Theodore HuertaDeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, United States.
Francesca A VozaDeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, United States.
Yulexi Y OrtizDeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, United States.
Zhao-Jun LiuDeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, United States.
Omaida C VelazquezDeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, United States.
University of Miami · US

Funding

Targeted cell delivery for treatment of non-healing wounds and gangreneR01HL149452 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI DAUNERT, SYLVIA, LIU, ZHAO-JUN · 2019 to 2022
$2.8M
Novel Gene Therapy for Critical Limb Ischemia and Limb Salvage in Vascular Occlusive DiseaseR33HL156152 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LIU, ZHAO-JUN, VELAZQUEZ, OMAIDA C · 2023 to 2024
$1.1M
Novel Gene Therapy for Critical Limb Ischemia and Limb Salvage in Vascular Occlusive DiseaseR61HL156152 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LIU, ZHAO-JUN, VELAZQUEZ, OMAIDA C · 2022 to 2022
$533k
NHLBI NIH HHS R01 HL149452NHLBI NIH HHS R33 HL156152NHLBI NIH HHS R61 HL156152
6 · The paper itself

Abstract

Progressive peripheral arterial disease (PAD) can result in chronic limb-threatening ischemia (CLTI) characterized by clinical complications including rest pain, gangrene and tissue loss. These complications can propagate even more precipitously in the setting of common concomitant diseases in patients with CLTI such as diabetes mellitus (DM). CLTI ulcers are cutaneous, non-healing wounds that persist due to the reduced perfusion and dysfunctional neovascularization associated with severe PAD. Existing therapies for CLTI are primarily limited to anatomic revascularization and medical management of contributing factors such as atherosclerosis and glycemic control. However, many patients fail these treatment strategies and are considered "no-option," thereby requiring extremity amputation, particularly if non-healing wounds become infected or fulminant gangrene develops. Given the high economic burden imposed on patients, decreased quality of life, and poor survival of no-option CLTI patients, regenerative therapies aimed at neovascularization to improve wound healing and limb salvage hold significant promise. Cell-based therapy, specifically utilizing mesenchymal stem/stromal cells (MSCs), is one such regenerative strategy to stimulate therapeutic angiogenesis and tissue regeneration. Although previous reviews have focused primarily on revascularization outcomes after MSC treatments of CLTI with less attention given to their effects on wound healing, here we review advances in pre-clinical and clinical studies related to specific effects of MSC-based therapeutics upon ischemic non-healing wounds associated with CLTI.

Indexed as

cell-based therapychronic limb-threatening ischemiacritical limb ischemiadiabetic woundmesenchymal stem (stromal) cellPeripheral Arterial Diseasestem cell therapywound healing

Identifiers

PMID36818343
PMCPMC9930203
OpenAlexW4318775826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.